Kura Oncology, Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
KURA$7.57+4.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
(In thousands, except par value data)
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $149,099 | $224,462 |
| Short-term investments | 518,141 | 502,933 |
| Accounts receivable, net | 8,804 | 2,060 |
| Inventory | 413 | — |
| Prepaid expenses and other current assets | 32,206 | 15,374 |
| Total current assets | 708,663 | 744,829 |
| Property and equipment, net | 7,855 | 1,682 |
| Operating lease right-of-use assets | 7,302 | 5,803 |
| Other long-term assets | 14,543 | 7,845 |
| Total assets | $738,363 | $760,159 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities | ||
| Accounts payable | $5,017 | $1,469 |
| Accrued expenses and other current liabilities | 61,697 | 48,484 |
| Current operating lease liabilities | 1,277 | 1,881 |
| Current portion of long-term debt | — | 2,607 |
| Current portion of contract liabilities | 48,983 | 24,271 |
| Total current liabilities | 116,974 | 78,712 |
| Long-term debt, net of current portion | 9,711 | 6,916 |
| Long-term operating lease liabilities | 9,469 | 5,190 |
| Other long-term liabilities | 3,165 | 1,795 |
| Long-term contract liabilities | 424,909 | 253,906 |
| Total liabilities | 564,228 | 346,519 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares issued and outstanding | — | — |
| Common stock, $0.0001 par value; 200,000 shares authorized; 87,855 and 78,229 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 9 | 8 |
| Additional paid-in capital | 1,347,190 | 1,308,290 |
| Accumulated other comprehensive income | 1,024 | 764 |
| Accumulated deficit | (1,174,088) | (895,422) |
| Total stockholders’ equity | 174,135 | 413,640 |
| Total liabilities and stockholders’ equity | $738,363 | $760,159 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.